Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ambitious Schedule For OTC Monograph Updates On FDA Unified Agenda

This article was originally published in The Tan Sheet

Executive Summary

Nearly two-thirds of FDA’s planned regulatory actions for the consumer health segment would update the OTC drug monograph, including changes to pediatric cough/cold labeling, acetaminophen dosing, oral care products with benzocaine and labeling for some laxatives.

You may also be interested in...



E-Cigarette Workshops Aim To Fill Information Gaps Prior To FDA Regulation

The first of three workshops, Dec. 10-11, will focus on device designs, liquid nicotine and other ingredients, aerosol constituents, packaging, constituent labeling and environmental impact. The workshops are not for commenting on a proposed rule deeming cigars, pipe tobacco and electronic nicotine delivery devices subject to FDA’s authority.

E-Cigarette Workshops Aim To Fill Information Gaps Prior To FDA Regulation

The first of three workshops, Dec. 10-11, will focus on device designs, liquid nicotine and other ingredients, aerosol constituents, packaging, constituent labeling and environmental impact. The workshops are not for commenting on a proposed rule deeming cigars, pipe tobacco and electronic nicotine delivery devices subject to FDA’s authority.

OTC Benzocaine Needs Label Warning, Indication Change – Public Citizen

In a citizen petition the group asks FDA to remove teething for children 2 years and older as an indication for some benzocaine products and require a label warning for OTC monograph benzocaine products concerning the risk of methemoglobinemia.

Related Content

Topics

UsernamePublicRestriction

Register

MT142464

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel